Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DAB2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DAB2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DAB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DAB2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DAB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004354210 | Oral cavity | EOLP | endothelial cell migration | 59/2218 | 279/18723 | 6.05e-06 | 1.19e-04 | 59 |
GO:190336426 | Oral cavity | EOLP | positive regulation of cellular protein catabolic process | 38/2218 | 155/18723 | 8.47e-06 | 1.61e-04 | 38 |
GO:006082823 | Oral cavity | EOLP | regulation of canonical Wnt signaling pathway | 54/2218 | 253/18723 | 1.11e-05 | 1.95e-04 | 54 |
GO:000862521 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway via death domain receptors | 24/2218 | 82/18723 | 1.73e-05 | 2.84e-04 | 24 |
GO:004586017 | Oral cavity | EOLP | positive regulation of protein kinase activity | 74/2218 | 386/18723 | 1.78e-05 | 2.89e-04 | 74 |
GO:006007023 | Oral cavity | EOLP | canonical Wnt signaling pathway | 61/2218 | 303/18723 | 2.11e-05 | 3.28e-04 | 61 |
GO:000222411 | Oral cavity | EOLP | toll-like receptor signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:003812723 | Oral cavity | EOLP | ERBB signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:006220713 | Oral cavity | EOLP | regulation of pattern recognition receptor signaling pathway | 28/2218 | 105/18723 | 2.46e-05 | 3.65e-04 | 28 |
GO:005109021 | Oral cavity | EOLP | regulation of DNA-binding transcription factor activity | 80/2218 | 440/18723 | 5.77e-05 | 7.31e-04 | 80 |
GO:004308714 | Oral cavity | EOLP | regulation of GTPase activity | 66/2218 | 348/18723 | 6.92e-05 | 8.55e-04 | 66 |
GO:003249623 | Oral cavity | EOLP | response to lipopolysaccharide | 65/2218 | 343/18723 | 8.02e-05 | 9.65e-04 | 65 |
GO:007005923 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 19/2218 | 63/18723 | 8.12e-05 | 9.69e-04 | 19 |
GO:190010121 | Oral cavity | EOLP | regulation of endoplasmic reticulum unfolded protein response | 12/2218 | 30/18723 | 8.20e-05 | 9.77e-04 | 12 |
GO:004340521 | Oral cavity | EOLP | regulation of MAP kinase activity | 39/2218 | 177/18723 | 8.57e-05 | 1.02e-03 | 39 |
GO:003096822 | Oral cavity | EOLP | endoplasmic reticulum unfolded protein response | 21/2218 | 74/18723 | 9.37e-05 | 1.09e-03 | 21 |
GO:005134625 | Oral cavity | EOLP | negative regulation of hydrolase activity | 70/2218 | 379/18723 | 9.98e-05 | 1.14e-03 | 70 |
GO:000717316 | Oral cavity | EOLP | epidermal growth factor receptor signaling pathway | 27/2218 | 108/18723 | 1.14e-04 | 1.27e-03 | 27 |
GO:007190121 | Oral cavity | EOLP | negative regulation of protein serine/threonine kinase activity | 29/2218 | 120/18723 | 1.24e-04 | 1.37e-03 | 29 |
GO:004340924 | Oral cavity | EOLP | negative regulation of MAPK cascade | 39/2218 | 180/18723 | 1.25e-04 | 1.38e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DAB2 | SNV | Missense_Mutation | | c.1639N>A | p.Gly547Ser | p.G547S | P98082 | protein_coding | tolerated(0.28) | benign(0.043) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | SNV | Missense_Mutation | rs376782436 | c.1729G>A | p.Ala577Thr | p.A577T | P98082 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1797N>A | p.Phe599Leu | p.F599L | P98082 | protein_coding | deleterious(0.03) | possibly_damaging(0.459) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DAB2 | SNV | Missense_Mutation | | c.5C>T | p.Ser2Phe | p.S2F | P98082 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DAB2 | SNV | Missense_Mutation | | c.796N>G | p.Pro266Ala | p.P266A | P98082 | protein_coding | deleterious(0.05) | possibly_damaging(0.62) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DAB2 | SNV | Missense_Mutation | | c.2277N>C | p.Glu759Asp | p.E759D | P98082 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1546N>G | p.Thr516Ala | p.T516A | P98082 | protein_coding | tolerated(0.93) | benign(0) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | SNV | Missense_Mutation | novel | c.1931N>T | p.Gly644Val | p.G644V | P98082 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
DAB2 | insertion | Nonsense_Mutation | novel | c.1317_1318insTGACTCTTTTGCTTTTGCTCATAAAATGATGATGCATC | p.Gly440Ter | p.G440* | P98082 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DAB2 | insertion | Nonsense_Mutation | novel | c.1581_1582insACTTTGATGCTAATCAACTATTGA | p.Met527_Ala528insThrLeuMetLeuIleAsnTyrTer | p.M527_A528insTLMLINY* | P98082 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |